CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to GILD

Sacituzumab govitecan-hziy (SG)

Phase 3
Gilead Sciences, Inc. (GILD)

Phase 3

Development Phase

2

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Jun '27
GILDPhase 3

Sacituzumab govitecan-hziy (SG) Phase 3 Est. Readout

Sacituzumab govitecan-hziy (SG)
Jun 2027~STALE
CT.gov
00%
Jun '27
GILDPhase 2

Sacituzumab govitecan-hziy (SG) Phase 2 Est. Readout

Sacituzumab govitecan-hziy (SG)
Jun 2027~STALE
CT.gov
00%
Competitive Landscape

3 competitors in Triple Negative Breast Cancer

View Full Landscape
Drug Information

Target Indication

Triple Negative Breast Cancer

Clinical Trial

NCT05633654

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.